On 7 November, biopharmaceutical company Khondrion announced the publication of results from their integrated Phase 2b clinical development programme which uses the drug sonlicromanol to target the underlying pathways of primary mitochondrial disease.
Help raise awareness of the symptoms of TK2D by sharing our fantastic infographics. We’ve slightly updated these from 2023, so please do replace your older graphics with these ones.
Download the version in English or landscape version in English, or follow the links for versions in Italian, Spanish, and German:
Hello there
The results of the forums have been published in two reports (see links below). They captured the key discussions and provided people living with LHON the important opportunity to connect on critical issues, share experiences and make recommendations.
Theme: LHON & Gene Therapy: Where are we now?
Save the date for a free, interactive webinar discussing gene therapy and LHON.
Hear the latest from companies developing gene therapies for LHON, clinical experts and someone who has been part of a gene therapy clinical trial. And find out what you can do to ensure the voice of people living with LHON is heard!
Our webinar will be on 19 September 2024 from 13:00 – 15:00 CEST. To register your interest click on the link below.